famotidine has been researched along with Chronic Illness in 24 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twelve patients with stable congestive heart failure and left ventricular dysfunction were enrolled in a double-blind, randomized crossover trial of famotidine, cimetidine and placebo to determine whether histamine type 2 (H2) antagonists adversely affect left ventricular systolic performance." | 9.07 | Effects of histamine type 2-receptor antagonists cimetidine and famotidine on left ventricular systolic function in chronic congestive heart failure. ( Jarboe, LA; Lee, RT; Solomon, SD; Wolfe, MM; Wolff, S, 1993) |
| "The new H2 receptor antagonist, famotidine, has been tested in open and double-blind studies in over 2,000 acute duodenal or gastric ulcer patients as well as in the maintenance of chronic duodenal ulcer patients." | 9.05 | Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience. ( Bianchi Porro, G, 1985) |
| "In this multicenter prospective single-arm open-label study, 10,311 patients with a clinical diagnosis of chronic symptomatic gastritis were enrolled and each patient was administered famotidine at 20 mg/day for 4 weeks." | 7.78 | Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study. ( Chiba, T; Kinoshita, Y, 2012) |
| "To assess the synergistic action of famotidine (FMD) and chlorpheniramine (CPA) on acetic acid-induced chronic gastric ulcer in rats." | 7.73 | Synergistic action of famotidine and chlorpheniramine on acetic acid-induced chronic gastric ulcer in rats. ( Chen, C; Qin, Z, 2005) |
| "The acute effects of histamine H2 receptor antagonist, famotidine, on hepatic hemodynamics were studied in six normal volunteers and eight patients with chronic liver disease, and its chronic effects on peptic ulcer, portal hemodynamics, and hepatic function were studied in 20 patients with chronic liver disease and peptic ulcer (16 with gastric ulcer, four with duodenal ulcer)." | 7.67 | Effect of famotidine on hepatic hemodynamics and peptic ulcer. ( Goto, N; Nomura, F; Ohnishi, K; Ohtsuki, T; Okuda, K; Saito, M; Suzuki, N; Takashi, M, 1987) |
| "When lafutidine (3, 10 mg/kg) was administered orally once daily for one week after the withdrawal of ammonia or TCA solution, the recovery of the mucosal thickness in the fundic gland area and the parietal cell number were significantly accelerated, and the recovery of mucosal thickness in the pyloric gland area also tended to be accelerated." | 5.30 | [Effect of a novel antiulcer drug, lafutidine, on experimental chronic gastritis in rats]. ( Inaba, N; Onodera, S; Shibata, M; Suzuki, T; Tanaka, M; Yamaura, T, 1997) |
| "Famotidine clearance was reduced only in patients with decompensated cirrhosis, probably because of concomitant renal impairment." | 5.28 | Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer. ( Ohnishi, K, 1990) |
| "Five patients with gastroesophageal reflux disease (GERD), who also had chronic functional diarrhea and postprandial urgency, unexpectedly noted rapid relief of their diarrhea and urgency when they took lansoprazole for their heartburn." | 5.09 | Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea. ( Dave, B; Rubin, W, 1999) |
| "The aim of the study was to assess effects of H2-blocker of the IIId generation famotidine (quamatel) on the progression of acute and chronic pancreatitis and intensity of pain in patients with pancreatitis." | 5.09 | [Quamatel in the treatment of acute and chronic pancreatitis]. ( Belousova, EA; Dolgova, MB; Filizhanko, VN; Lovakov, AI; Nikulin, IV; Shemeneva, EG; Zlatkin, AR, 2000) |
| "Twelve patients with stable congestive heart failure and left ventricular dysfunction were enrolled in a double-blind, randomized crossover trial of famotidine, cimetidine and placebo to determine whether histamine type 2 (H2) antagonists adversely affect left ventricular systolic performance." | 5.07 | Effects of histamine type 2-receptor antagonists cimetidine and famotidine on left ventricular systolic function in chronic congestive heart failure. ( Jarboe, LA; Lee, RT; Solomon, SD; Wolfe, MM; Wolff, S, 1993) |
| "In a two center open uncontrolled clinical trial, the efficacy of a single evening dose of 40 mg famotidine (Ulcusan) was studied in a total of 37 patients (20 with chronic duodenal ulcers, 9 with recurring and 8 with acute gastric ulcers)." | 5.07 | [Therapy of peptic ulcers with famotidine. Report of experiences with an open clinical study]. ( Dragosics, B; Okulski, G; Weiss, W, 1992) |
| "The new H2 receptor antagonist, famotidine, has been tested in open and double-blind studies in over 2,000 acute duodenal or gastric ulcer patients as well as in the maintenance of chronic duodenal ulcer patients." | 5.05 | Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience. ( Bianchi Porro, G, 1985) |
| "In this multicenter prospective single-arm open-label study, 10,311 patients with a clinical diagnosis of chronic symptomatic gastritis were enrolled and each patient was administered famotidine at 20 mg/day for 4 weeks." | 3.78 | Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study. ( Chiba, T; Kinoshita, Y, 2012) |
| "To assess the synergistic action of famotidine (FMD) and chlorpheniramine (CPA) on acetic acid-induced chronic gastric ulcer in rats." | 3.73 | Synergistic action of famotidine and chlorpheniramine on acetic acid-induced chronic gastric ulcer in rats. ( Chen, C; Qin, Z, 2005) |
| "The pharmacokinetics of famotidine were studied after the administration of a single intravenous dose of 20-mg to seven normal volunteers, six patients with chronic hepatitis, 14 patients with compensated cirrhosis, and seven patients with decompensated cirrhosis." | 3.68 | Pharmacokinetics of famotidine after intravenous administration in liver disease. ( Ohnishi, K, 1991) |
| "The acute effects of histamine H2 receptor antagonist, famotidine, on hepatic hemodynamics were studied in six normal volunteers and eight patients with chronic liver disease, and its chronic effects on peptic ulcer, portal hemodynamics, and hepatic function were studied in 20 patients with chronic liver disease and peptic ulcer (16 with gastric ulcer, four with duodenal ulcer)." | 3.67 | Effect of famotidine on hepatic hemodynamics and peptic ulcer. ( Goto, N; Nomura, F; Ohnishi, K; Ohtsuki, T; Okuda, K; Saito, M; Suzuki, N; Takashi, M, 1987) |
| "When lafutidine (3, 10 mg/kg) was administered orally once daily for one week after the withdrawal of ammonia or TCA solution, the recovery of the mucosal thickness in the fundic gland area and the parietal cell number were significantly accelerated, and the recovery of mucosal thickness in the pyloric gland area also tended to be accelerated." | 1.30 | [Effect of a novel antiulcer drug, lafutidine, on experimental chronic gastritis in rats]. ( Inaba, N; Onodera, S; Shibata, M; Suzuki, T; Tanaka, M; Yamaura, T, 1997) |
| " The YM022 dosage required to inhibit basal acid secretion is consistent with that required to suppress pentagastrin-induced acid secretion." | 1.29 | Comparative evaluation of the role of endogenous gastrin in basal acid secretion in conscious rats provided with chronic fistula and pylorus ligation. ( Akuzawa, S; Miyata, K; Nishida, A; Takemoto, Y; Uchida-Kobayashi, A, 1996) |
| " The mean half-life in the compensated cirrhotics, 2." | 1.28 | Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. ( Cottrell, J; Mann, SG; Morgan, MY; Stambuk, D, 1990) |
| "Famotidine clearance was reduced only in patients with decompensated cirrhosis, probably because of concomitant renal impairment." | 1.28 | Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer. ( Ohnishi, K, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.50) | 18.7374 |
| 1990's | 12 (50.00) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 3 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrecchia, CE | 1 |
| Hobbs, TR | 1 |
| Andrade, C | 1 |
| Wan, KS | 1 |
| Kinoshita, Y | 1 |
| Chiba, T | 1 |
| Filimonov, RM | 1 |
| Musaeva, OM | 1 |
| Qin, Z | 1 |
| Chen, C | 1 |
| Kim, J | 1 |
| Ogai, A | 1 |
| Nakatani, S | 1 |
| Hashimura, K | 1 |
| Kanzaki, H | 1 |
| Komamura, K | 1 |
| Asakura, M | 1 |
| Asanuma, H | 1 |
| Kitamura, S | 1 |
| Tomoike, H | 1 |
| Kitakaze, M | 1 |
| Kolck, UW | 1 |
| Alfter, K | 1 |
| Homann, J | 1 |
| von Kügelgen, I | 1 |
| Molderings, GJ | 1 |
| Shiratori, K | 1 |
| Watanabe, S | 1 |
| Maruyama, M | 1 |
| Adachi, H | 1 |
| Itoh, Y | 1 |
| Kurokawa, K | 1 |
| Takeuchi, T | 1 |
| Hanson, DG | 1 |
| Kamel, PL | 1 |
| Kahrilas, PJ | 1 |
| Solomon, SD | 1 |
| Wolff, S | 1 |
| Jarboe, LA | 1 |
| Wolfe, MM | 1 |
| Lee, RT | 1 |
| Prell, GD | 1 |
| Rosse, RB | 1 |
| Deutsch, SI | 1 |
| Nishida, A | 1 |
| Uchida-Kobayashi, A | 1 |
| Takemoto, Y | 1 |
| Akuzawa, S | 1 |
| Miyata, K | 1 |
| Onodera, S | 1 |
| Tanaka, M | 1 |
| Inaba, N | 1 |
| Suzuki, T | 1 |
| Shibata, M | 1 |
| Yamaura, T | 1 |
| Malov, IuS | 1 |
| Kulikov, AN | 1 |
| Dave, B | 1 |
| Rubin, W | 1 |
| Belousova, EA | 1 |
| Zlatkin, AR | 1 |
| Nikulin, IV | 1 |
| Lovakov, AI | 1 |
| Filizhanko, VN | 1 |
| Shemeneva, EG | 1 |
| Dolgova, MB | 1 |
| Dragosics, B | 1 |
| Weiss, W | 1 |
| Okulski, G | 1 |
| Ohnishi, K | 3 |
| Sekiguchi, T | 1 |
| Nishioka, T | 1 |
| Matsuzaki, T | 1 |
| Sugiyama, M | 1 |
| Kusano, M | 1 |
| Horikoshi, T | 1 |
| Toki, M | 1 |
| Ohwada, T | 1 |
| Kobayashi, S | 1 |
| Morgan, MY | 1 |
| Stambuk, D | 1 |
| Cottrell, J | 1 |
| Mann, SG | 1 |
| Bianchi Porro, G | 1 |
| Saito, M | 1 |
| Nomura, F | 1 |
| Okuda, K | 1 |
| Suzuki, N | 1 |
| Ohtsuki, T | 1 |
| Goto, N | 1 |
| Takashi, M | 1 |
9 trials available for famotidine and Chronic Illness
| Article | Year |
|---|---|
Efficacy of oral fecal bacteriotherapy in rhesus macaques (Macaca mulatta) with chronic diarrhea.
Topics: Administration, Oral; Analysis of Variance; Animals; Animals, Laboratory; Biological Therapy; Chroni | 2013 |
Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria.
Topics: Acetates; Adolescent; Adult; Cetirizine; Chronic Disease; Cyclopropanes; Drug Therapy, Combination; | 2009 |
[Laser therapy and famotidine in complex restorative treatment of primary chronic gastroduodenitis].
Topics: Chronic Disease; Combined Modality Therapy; Duodenitis; Famotidine; Female; Histamine H2 Antagonists | 2003 |
Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies.
Topics: Aged; Cardiac Output, Low; Chronic Disease; Famotidine; Female; Gastroesophageal Reflux; Histamine H | 2006 |
Effects of histamine type 2-receptor antagonists cimetidine and famotidine on left ventricular systolic function in chronic congestive heart failure.
Topics: Aged; Analysis of Variance; Chronic Disease; Cimetidine; Double-Blind Method; Echocardiography; Famo | 1993 |
Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Chronic Disease; Colonic Disea | 1999 |
[Quamatel in the treatment of acute and chronic pancreatitis].
Topics: Acute Disease; Adult; Chronic Disease; Disease Progression; Famotidine; Female; Histamine H2 Antagon | 2000 |
[Therapy of peptic ulcers with famotidine. Report of experiences with an open clinical study].
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Dose-Response Relationship, Drug; Drug Administrati | 1992 |
Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience.
Topics: Acute Disease; Chronic Disease; Cimetidine; Circadian Rhythm; Clinical Trials as Topic; Double-Blind | 1985 |
15 other studies available for famotidine and Chronic Illness
| Article | Year |
|---|---|
Famotidine augmentation in schizophrenia: hope or hype?
Topics: Antipsychotic Agents; Chronic Disease; Drug Synergism; Evidence-Based Medicine; Famotidine; Histamin | 2013 |
Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study.
Topics: Adult; Aged; Chronic Disease; Dyspepsia; Famotidine; Female; Gastritis; Heartburn; Histamine H2 Anta | 2012 |
Synergistic action of famotidine and chlorpheniramine on acetic acid-induced chronic gastric ulcer in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Acetic Acid; Animals; Chlorpheniramine; Chronic Disease; Drug Synergis | 2005 |
Cardiac mast cells: implications for heart failure.
Topics: Chronic Disease; Famotidine; Female; Heart Failure; Humans; Male; Mast Cells; Mastocytosis, Systemic | 2007 |
[A case of refractory chronic Zollinger-Ellison syndrome--treated successfully with famotidine].
Topics: Chronic Disease; Esophageal Diseases; Esophagogastric Junction; Famotidine; Histamine H2 Antagonists | 1984 |
Outcomes of antireflux therapy for the treatment of chronic laryngitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Chronic Disease; Famotidine; Female; Gastroesopha | 1995 |
Apparent absence of famotidine-antipsychotic drug interactions in patients with chronic schizophrenia.
Topics: Antipsychotic Agents; Brain; Chronic Disease; Famotidine; Histamine H2 Antagonists; Humans; Schizoph | 1996 |
Comparative evaluation of the role of endogenous gastrin in basal acid secretion in conscious rats provided with chronic fistula and pylorus ligation.
Topics: Animals; Atropine; Benzodiazepines; Chronic Disease; Famotidine; Gastric Acid; Gastric Fistula; Gast | 1996 |
[Effect of a novel antiulcer drug, lafutidine, on experimental chronic gastritis in rats].
Topics: Acetamides; Ammonia; Animals; Anti-Ulcer Agents; Cell Count; Chronic Disease; Cimetidine; Famotidine | 1997 |
[Bicarbonate deficiency and duodenal peptic ulcer].
Topics: Acid-Base Equilibrium; Adult; Bicarbonates; Chronic Disease; Duodenal Ulcer; Famotidine; Female; Gas | 1998 |
Pharmacokinetics of famotidine after intravenous administration in liver disease.
Topics: Adult; Aged; Chronic Disease; Famotidine; Female; Half-Life; Hepatitis; Humans; Infusions, Intraveno | 1991 |
Comparative efficacy of acid reflux inhibition by drug therapy in reflux esophagitis.
Topics: Adult; Aged; Chronic Disease; Cisapride; Esophagitis, Peptic; Esophagus; Famotidine; Female; Humans; | 1991 |
Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease.
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Chronic Disease; Famotidine | 1990 |
Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer.
Topics: Adult; Chronic Disease; Famotidine; Female; Hepatitis; Humans; Liver Circulation; Liver Cirrhosis; L | 1990 |
Effect of famotidine on hepatic hemodynamics and peptic ulcer.
Topics: Adult; Chronic Disease; Dye Dilution Technique; Famotidine; Female; Hemodynamics; Histamine H2 Antag | 1987 |